Quest Diagnostics (DGX) Change in Receivables (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Change in Receivables data on file, last reported at $180.0 million in Q1 2026.

• Quarterly Change in Receivables rose 78.22% year-over-year to $180.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $185.0 million (up 218.97% YoY) and the FY2025 annual result came in at $106.0 million, up 49.3% from the prior year.
• Change in Receivables rose to $180.0 million in Q1 2026 per DGX's latest filing, from -$47.0 million in the prior quarter.
• The five-year high for Change in Receivables was $180.0 million in Q1 2026, with the low at -$84.0 million in Q4 2022.
• Average Change in Receivables over 5 years is $7.4 million, with a median of -$1.0 million recorded in 2024.
• Year-over-year, Change in Receivables plunged 133.33% in 2022 and surged 1500.0% in 2025.
• Quest Diagnostics' Change in Receivables stood at -$84.0 million in 2022, then gained by 15.48% to -$71.0 million in 2023, then advanced by 2.82% to -$69.0 million in 2024, then surged by 31.88% to -$47.0 million in 2025, then jumped by 482.98% to $180.0 million in 2026.
• Business Quant data shows DGX's Change in Receivables at $180.0 million in Q1 2026, -$47.0 million in Q4 2025, and $38.0 million in Q3 2025.